Xilio Therapeutics Announces Proposed Public Offering

Core Viewpoint - Xilio Therapeutics, Inc. is initiating an underwritten public offering of pre-funded warrants and various series of warrants to purchase shares of common stock, aimed at advancing its product candidates and supporting general corporate needs [1][2]. Group 1: Offering Details - The public offering includes pre-funded warrants and Series A, B, and C warrants for purchasing common stock, all offered by Xilio [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the specific terms [1]. - Leerink Partners is acting as the sole bookrunner for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to further develop product candidates and for working capital and other corporate purposes [2]. Group 3: Regulatory Information - A shelf registration statement related to the securities was filed with the SEC on March 11, 2025, and was declared effective on May 8, 2025 [3]. - The offering will be conducted through a prospectus supplement and accompanying prospectus, which will be available on the SEC's website [3]. Group 4: Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies to improve cancer treatment outcomes while minimizing systemic side effects [5]. - The company is leveraging a proprietary platform to advance a pipeline of novel, tumor-activated immuno-oncology molecules [5].